Decreasing the amount of active mouse Ets2 transcription factor by half in mice or use of a MAP kinase insensitive hypomorphic targeted Ets2 allele restricts the appearance of transgenic mammary tumors caused by either Polyoma middle T antigen (PyMT) or activated Neu/ErbB2. In addition, the early growth of transplanted mammary tumors is limited by restricted Ets2 activity of the host. Here we have tested genetically, with the use of a conditional Ets2 flox allele and tissue specific Cre recombinase expression, whether Ets2 also functions within tumor cells by inactivating Ets2 within mammary luminal epithelial cells from which transgenic PyMT Y315/322F tumors arise. We find that inactivation of Ets2 within tumor cells has no effect on tumor appearance or growth. By contrast, complete inactivation of Ets2 in both epithelial and stromal cells moderates the early hyperplastic phase of tumor development and the time of tumor appearance but does not prevent tumor occurrence and has no detectable effect on tumor growth. Thus, Ets2 supports mammary tumors exclusively through their microenvironment.
Introduction
Genetic restrictions of the transcription factor Ets2 limit mouse mammary tumor development caused by transgenic expression of either Polyoma middle T antigen (PyMT) or activated Neu/ErbB2 (Neznanov et al., 1999) . Targeted deletion of the Ets2 DNA-binding domain (Ets2 db1 ) or mutation of the unique, activating MAPK phosphorylation site (Ets2 A72 ) revealed that Ets2 supports both autochthonous and transplanted mammary tumors (Man et al., 2003) . The Ets2-dependent host effect on transplanted tumors showed that at least part of the function of Ets2 was mediated through the stroma (Man et al., 2003) . However, a possible epithelial role for Ets2 is suggested by reversal of the transformed phenotype of BT20 breast tumor cells by a dominantnegative Ets2 construct (Sapi et al., 1998) , but such constructs also broadly inhibit Ets family transcription factor function (Hever et al., 2003) . As Ets2 is regulated by oncogene activation of MAP kinase pathways, does it also function within tumor cells or only in stromal support? As previous studies dealt with only decreased Ets2 activity, we tested whether mammary tumors would develop in adult mice nearly devoid of Ets2 function. We have addressed these questions using a conditional Ets2 allele (Ets2 flox ) that is inactivated by Cre recombinase (Cre). We show that Ets2 deficiency delays mammary tumor development, but tumors can form in the near absence of Ets2. We also show that mammary tumor development is not influenced by Ets2 deficiency in mammary epithelial cells. Thus, Ets2 supports mammary tumors exclusively through a stromal mechanism.
Results

Recombination of the Ets2 flox allele
To circumvent early embryonic lethality by inactivation of Ets2 (Yamamoto et al., 1998) , a conditionally targeted Ets2 allele (Ets2 flox ) was generated (Wen, Cecena and Oshima, in preparation). Ets2 flox ( Figure 1a ) contains loxP sequences flanking exons 9 and 10, encoding the C-terminal portion of the Ets2 DNA-binding domain. Cre converts Ets2 flox to Ets2 db2 resulting in an inactive Ets2 protein lacking a functional DNA-binding domain. Ets2 flox/flox mice were normal, while developmental studies confirmed the lethality of Ets2 db2/db2 embryos and their similarity to the previously described Ets2 db1/db1 embryos (Wen, Cecena and Oshima, in preparation).
To determine the degree to which complete loss of Ets2 function would impair mammary tumor formation, we used the Mox2-Cre mouse (MORE) to express Cre in an epiblast-restricted manner (Tallquist and Soriano, 2000) . MORE mice were shown to express Cre in all primitive ectoderm derivatives by E7, but not in extraembryonic endoderm or trophectoderm derivatives. This allows targeted recombination of loxP flanked alleles in all adult tissues of endodermal, ectodermal, and mesodermal lineages.
When Ets2 flox/ þ ;MORE mice were crossed to Ets2 ;MMTV-Cre7 mice (Figure 1b ) due to the epithelial-specific Cre expression from MMTV-Cre7 mice (Andrechek et al., 2000) and the mixture of cell types found in the mammary gland.
Restriction of mammary tumors by limited Ets2
MMTV-mediated expression of the PyMT oncogene within the mammary epithelium has been used to generate mouse models of breast cancer (Guy et al., 1992) . PyMT expression induced hyperplastic mammary epithelium capable of forming multifocal tumors with metastatic potential. Transgenic mice that express a mutant form of PyMT (PyMT Y315/322F ) limited the ability of PyMT to signal through the PI3K pathway and resulted in an extended hyperplastic phase (Webster et al., 1998 mice developed tumors with a median onset of 137 days (Figure 1c ). In contrast, Ets2 flox/db2 ;MORE;PyMT Y315/322F mice developed tumors with a median onset of 174 days, a significant delay of 37 days (log rank, P ¼ 0.007). However, once tumors appeared, the rate of tumor growth was not detectably altered by Ets2 deficiency (Figure 1d ). These results are similar to the effect of a single targeted Ets2 allele on MMTV-PyMT tumor appearance and growth (Neznanov et al., 1999 (Figure 2a ). Most tumors from mice of both groups had significant levels of Ets2 recombination (Figure 2a, 6, 7, 9) . Unexpectedly, a number of tumors had nonrecombined Equivalent levels of PyMT Y315/322F mRNA were found in tumors with different Ets2 activities (Figure 2b ). Thus the Ets2-dependent restriction of PyMT Y315/322F tumors is not due to differential oncogene expression. As expected, Ets2 mRNA encoding the loxP flanked region of exons 9 and 10 was 16-20-fold less in tumors of the Ets2 db2/db2 genotype than in tumors of the other three possible Ets2 genotype combinations (Figure 2b ). This confirmed the expected molecular consequence of the Ets2 db2 deletion in tumors.
Ets2 deficiency alters early PyMT Y315/322F hyperplastic growth
The effect of Ets2 deficiency on tumor appearance and the lack of effect on tumor growth are consistent with a function for Ets2 during the early progression to frank tumor formation. The PyMT Y315/322F mouse model causes a uniform and extended hyperplastic phase preceding tumor development that interferes with the glandular epithelium filling of the fat pad (Figure 3c and e). This contrasts with both normal development (Figure 3a ) and the more rapid progression of tumors in the original wt PyMT mammary tumor model (Figure 3b ) (Guy et al., 1992 mice (Figure 3c-f) . The average distance from the nipple area to the edge of the hyperplastic growth as a function of fat pad length was 30% less in the more severely Ets2 deficient animals ( Figure 3g ). This restriction was specific for PyMT Y315/322F mammary glands as the mammary epithelial tree of virgin Ets2 flox/db2
;MORE females at 4 and 8 weeks was normal (data not shown).
Mammary epithelial Ets2 does not regulate tumor development
We used MMTV-Cre7 transgenic mice (Andrechek et al., 2000) -induced tumor formation from a median time of 137 to 174 days, but subsequent tumor growth was indistinguishable between mice of either Ets2 genotype. These data suggest that Ets2 may regulate tumor development at an early initiation phase. The Ets2-dependent differences in the morphology of PyMT Y315/322F hyperplastic growth support this view. The remarkable aspect of this difference is that it is likely due to stromal cell effects on hyperplastic epithelial cell organization because inactivation of Ets2 within the mammary epithelium by MMTV-Cre7 did not result in such differences in hyperplastic outgrowth (data not shown). The loss of Ets2 within the mammary epithelium does not affect time of tumor onset, and there was no detectable genetic selection for tumors with an active Ets2 flox allele. Thus, in spite of the known activation of Ets2 downstream of growth factor stimulated MAP kinases, Ets2 does not play a key role in PyMT Y315/322F tumor cells. The strictly stromal role complements previous studies showing that stromal-derived Ets2 function can regulate short-term transplanted tumor growth (Man et al., 2003) .
What is the key Ets2-dependent stromal cell type(s) that regulates mammary tumor progression? Endothelial cells and inflammatory cells are two distinct cell types that have a direct influence on tumor progression. Ets2 is integral for the inflammatory response of macrophages by regulating both matrix metalloproteases (Yamamoto et al., 1998; Man et al., 2003) and cytokines (Wei et al., 2004) , suggesting the possibility of an Ets2 regulation of mammary tumor formation via an inflammatory cell function. While Ets2 does not appear limiting for the production of VEGF in mammary tumors , many studies have implicated Ets1 function in endothelial cells (Wernert et al., 1992; Lelievre et al., 2001; Sato, 2001) . While Ets2 deficiency alone does not result in differences in CD31 positive tumor vasculature (Man et al., 2003) , Ets2 deficiency may impact the function or maturation of tumor vasculature as suggested by Factor VIII staining of transplanted tumors (Man et al., 2003) . Both Cre transgenes used in this study showed evidence of mosaic expression or even silent alleles. However, the frequency of recombination was still high enough to reveal the Ets2-dependent support of PyMT Y315/322F tumors. The mosaic nature of Cre expression in MORE mice has been noted previously (Hayashi et al., 2002) . The apparent mosaic Cre expression from MMTV-Cre7 was reflected in two ways. First, both recombined and nonrecombined tumors were identified in the same host. Secondly, multiple animals had no recombined Ets2 flox allele in any tumor. However, we were able to take advantage of the mosaic MMTV-Cre7 expression and found that there was no genetic selection for a functional Ets2 allele in mammary tumors.
The results of this study show that Ets2 deficiency limits the development of PyMT Y315/322F -initiated tumors exclusively through the stroma. Decreasing Ets2 activity slows the appearance of mammary tumors from a hyperplastic phase. It is possible that variation in the expression or activity of Ets2 within the human population may contribute to the variable progression of human breast cancers.
Materials and methods
Mice
Generation of Ets2 flox mice will be described elsewhere. Ets2 flox was backcrossed into the FVB/N genetic background four generations prior to this study. MORE mice on the C57BL/6J genetic background were purchased from the Jackson Laboratory (stock No. 003755). PyMT Y315/322F (Webster et al., 1998) . The percent Ets2 db2 allele was estimated from standard curves containing DNA mixtures of Ets2 flox or Ets2 db2 alleles.
Tumor studies
Animals were inspected for palpable tumors weekly in blinded manner. Once detected, the length and width of tumors were measured with calipers every 2-3 days. Tumor volume was estimated (length Â width 2 /2). Small tumor biopsies were dissected and used for genotype analysis by PCR. Unaffected or mildly-affected mammary glands were mounted on glass slides, fixed in Carnoy's fixative, and stained with carmine alum. Photographic documentation was performed with a Nikon Coolpix 990 camera and Adobe Photoshop software.
RNA analysis
RNA was prepared with Trizol (Invitrogen). cDNA was prepared from 4 mg of total RNA using oligo(dT) priming and Superscript II reverse transcriptase (Invitrogen), and cDNA levels were measured by real-time PCR in a LightCycler instrument using the SYBR Green I PCR kit and LightCycler software (Roche). Gene expression was normalized to cyclophilin A (Cph) levels. The two primers for each target were as follows: Cph, AGACCAGCAAGAAGATCACC and GGA AAATATGGAACCCAAAG; Ets2, CCTGTCAATCTTT CATCAGC and AGTTCTGCAGGTCACATACG (flox region); PyMT Y315/322F , CAGCAGGCATATAAGCAGCA and CACCTGGCATCACATTTGTC.
